Biomimetic nanovaccine based on erythrocyte membrane enhances immune response and protection against tilapia lake virus

Virology. 2023 Mar:580:41-49. doi: 10.1016/j.virol.2023.01.014. Epub 2023 Jan 30.

Abstract

An infectious disease emerged in recent years, Tilapia Lake Virus Disease (TiLVD), has severely restricted the development of global tilapia industry. Vaccination has proved potential strategy to prevent its causative agent Tilapia Lake Virus (TiLV) infectious. However, the response intensity of subunit vaccine is limited by its low immunogenicity, thus inclusion of adjuvants is required. Thus, we prepared a biomimetic nano-system (Cs-S2@M-M) with a particle size of ∼100 nm and an encapsulation efficiency of about 79.15% based on erythrocyte membrane. The immune response was detected after intramuscular injection to assess the effectiveness of the vaccine. The biomimetic system significantly up-regulates the expression of immune genes, enhances the activity of non-specific immune-related enzymes (P < 0.05) and improved relative percentage survival by 17.4%-26.1% in TiLV challenge. The biomimetic nano-system based on erythrocyte membrane induced significant immune response in tilapia and enhanced protection against TiLV, promising as a model for fish vaccines.

Keywords: Biomimetic nanoparticles; Erythrocyte membrane; Subunit vaccine; Tilapia lake virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomimetics
  • Erythrocyte Membrane
  • Fish Diseases*
  • Orthomyxoviridae* / genetics
  • Tilapia*